Original GlobalRPh source
- Product / population
- Preserved GlobalRPh source, not a freshly verified product label
- Renal measure
- Use the method specified in the original source
- Source revision
- Historical source; revision not established here
- Retrieved
- 2026-09-05 (not the revision date)
Historical source: not automatically current. Review current official labeling and separately attributed additions before use.
Historical pediatric/perinatal schedules are preserved, not a current neonatal-prophylaxis recommendation. The missing neonatal IV row has not been filled by extrapolation.
Adult treatment and IV preparation
HIV-1, with other antiretrovirals: 300 mg orally twice daily. When oral therapy cannot be used, 1 mg/kg IV at a constant rate over 1 hour every 4 hours, only until oral therapy is feasible.
Dilute the dose from the 20 mL vial in D5W to no greater than 4 mg/mL. The source reports physical/chemical stability 24 hours at room temperature or 48 hours at 2-8 C, but recommends administration within 8 hours at 25 C or 24 hours refrigerated as a microbial-contamination precaution. Inspect for particles/discoloration and discard if present. No rapid infusion, bolus or IM use.
Pediatric source dosing - age 4 weeks to under 18 years
Calculate carefully, check order transcription/dispensing/instructions, and do not exceed the adult dose. Assess ability to swallow capsules; use syrup when capsules are unsuitable.
Weight 4 to under 9 kg: 24 mg/kg/day as 12 mg/kg twice daily or 8 mg/kg three times daily.
Weight 9 to under 30 kg: 18 mg/kg/day as 9 mg/kg twice daily or 6 mg/kg three times daily.
Weight at least 30 kg: 600 mg/day as 300 mg twice daily or 200 mg three times daily.
Alternative BSA dosing: 480 mg/m2/day as 240 mg/m2 twice daily or 160 mg/m2 three times daily. BSA and weight calculations may differ.
Historical maternal-fetal prevention regimen
The source describes maternal treatment after 14 weeks of pregnancy: 100 mg orally five times daily until labor. During labor/delivery: 2 mg/kg total body weight IV over 1 hour, then 1 mg/kg/hour continuously until cord clamping.
Begin neonatal treatment within 12 hours after birth through age 6 weeks. Its reproduced table gives oral 2 mg/kg every 6 hours (8 mg/kg/day). It mentions IV administration if oral dosing is impossible, but does not reproduce a neonatal IV numeric row; none is inferred.
Hematologic monitoring and interruption
Toxicity depends on pretreatment marrow reserve, dose and duration. With poor reserve or advanced symptomatic HIV, monitor frequently. Hemoglobin may decline within 2-4 weeks; neutropenia usually appears after 6-8 weeks.
Significant anemia (hemoglobin below 7.5 g/dL or reduction greater than 25%) or neutropenia (granulocytes below 750/mm3 or reduction greater than 50%) may require interruption until marrow recovery. Interruption does not eliminate transfusion needs. Resumption may be considered after recovery, with measures such as recommended-dose epoetin alfa according to erythropoietin levels, indices and tolerability. Consider reducing zidovudine for pronounced anemia with interacting chronic therapy such as fluconazole or valproic acid.
Hepatic dysfunction/cirrhosis: insufficient data for a specific dose adjustment; frequently monitor hematologic toxicity.
Renal Dosing and dialysis
Cockcroft-Gault CrCl below 15 mL/min, HD or PD: 100 mg orally every 6-8 hours. The source describes an approximate IV equivalent of 1 mg/kg every 6-8 hours.